Evidence map›Paper›PMID 26076985›Full record

Trial reportJournal of thrombosis and thrombolysis2015

Body mass index predicts major bleeding risks in patients on warfarin.

Adedotun A Ogunsua, Sunkaru Touray, Justin K Lui, Tiffany Ip, Jorge V Escobar, Joel Gore

Abstract readClinical TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in Journal of thrombosis and thrombolysis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Sensitivity to warfarin following cardiac surgery.Therapeutic advances in drug safety · 2018
    Article
  10. Article
  11. Article
  12. Thrombosis in the setting of obesity or inflammatory bowel disease.Hematology. American Society of Hematology. Education Program · 2016
    Review
  13. Effects of Obesity on Warfarin Reversal With Vitamin K.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Adedotun A OgunsuaDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, 01655, USA. adedotun.ogunsua@umassmemorial.org.
Sunkaru TourayDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, 01655, USA.
Justin K LuiDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, 01655, USA.
Tiffany IpDepartment of Pharmacy, UMass Memorial Medical Center, Worcester, MA, 01655, USA.
Jorge V EscobarDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, 01655, USA.
Joel GoreDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA, 01655, USA.
University of Massachusetts Chan Medical School · USUMass Memorial Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the lack of an optimum dosing strategy in obese patients, warfarin remains the most commonly used anticoagulant. Body mass index (BMI) >30 has been linked to increased time to obtain a therapeutic international normalized ratio on initiation of warfarin as well as higher maintenance dose. Despite higher dosage requirements, few studies have examined the relationship between warfarin and bleeding events in obese individuals. We examined the performance of BMI in predicting the incidence of bleeding at an anticoagulation clinic (ACC) over a 1 year period. Eight hundred and sixty-three patients followed in the ACC over a 1 year period were evaluated for bleeds in relation to BMI [defined as weight (kg)/height (m(2))]. Seventy-one of the 863 patients had a bleeding event (8.2 %); mean age 69.5 years and 44 % females. BMI categories were normal weight (21 %), overweight (38 %), obese class I (21 %), II (9 %), and III (11.3 %), respectively. Prevalence of major and minor bleeding events were 4.4 and 3.8 %, respectively. In univariate analyses, hazard ratio (HR) for major bleeding risks increases with higher obesity categories (HR 1.3, 1.85, and 1.93 for classes I, II, III, respectively). In multivariable adjusted model obesity classes II and III significantly increased the risk of major bleeds (HR 1.84, p < 0.001). Bleeding risk is higher in obese compared to normal weight individuals who are on warfarin. These results suggests that BMI plays a role in bleeding events in patients on warfarin.

Indexed as

Body Mass IndexObesityAdultAgedAged, 80 and overAge FactorsFemaleHemorrhageHumansMaleMiddle AgedRetrospective StudiesRisk FactorsSex FactorsWarfarinWarfarinBleedingBMIThrombosisWarfarin

Identifiers

PMID26076985
OpenAlexW616455611

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.